Publicacions en col·laboració amb investigadors/es de Instituto de Investigación Sanitaria Gregorio Marañón (45)

2024

  1. Breast cancer risk for the joint exposure to metals and metalloids in women: Results from the EPIC-Spain cohort

    The Science of the total environment, Vol. 912, pp. 168816

2022

  1. A New Methodology to Estimate Drug Cost Avoidance in Clinical Trials: Development and Application

    Frontiers in Oncology, Vol. 12

  2. Clinical and Sociodemographic Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Recommendations in Breast Cancer Survivors—Health-EpiGEICAM Study

    Cancers, Vol. 14, Núm. 19

  3. HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping

    Cancers, Vol. 14, Núm. 3

  4. How we treat HR-positive, HER2-negative early breast cancer

    Future oncology (London, England), Vol. 18, Núm. 8, pp. 1003-1022

  5. Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study

    European Journal of Cancer, Vol. 168, pp. 12-24

  6. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

    The Lancet. Oncology, Vol. 23, Núm. 1, pp. 149-160

  7. Type does matter. Use VIRGIN olive oil as your preferred fat to reduce your risk of breast cancer: case-control EpiGEICAM study

    European Journal of Clinical Nutrition, Vol. 76, Núm. 9, pp. 1343-1346

2021

  1. Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts

    Scientific Reports, Vol. 11, Núm. 1

  2. Aggressiveness of end-of-life cancer care: what happens in clinical practice?

    Supportive Care in Cancer, Vol. 29, Núm. 6, pp. 3121-3127

  3. Anthracyclines strike back: Rediscovering non‐pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer

    Cancers, Vol. 13, Núm. 17

  4. Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice

    Supportive Care in Cancer, Vol. 29, Núm. 8, pp. 4673-4681

  5. Dpyd exome, mrna expression and uracil levels in early severe toxicity to fluoropyrimidines: An extreme phenotype approach

    Journal of Personalized Medicine, Vol. 11, Núm. 8

  6. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study

    European Journal of Cancer, Vol. 156, pp. 70-82

  7. Iterative variable selection for high-dimensional data: Prediction of pathological response in triple-negative breast cancer

    Mathematics, Vol. 9, Núm. 3, pp. 1-14

  8. Regulatory CDH4 Genetic Variants Associate With Risk to Develop Capecitabine-Induced Hand-Foot Syndrome

    Clinical Pharmacology and Therapeutics, Vol. 109, Núm. 2, pp. 462-470

  9. Technical challenges for CTC implementation in breast cancer

    Cancers, Vol. 13, Núm. 18

  10. Trajectories of alcohol consumption during life and the risk of developing breast cancer

    British Journal of Cancer, Vol. 125, Núm. 8, pp. 1168-1176

2020

  1. Incidence of venous thromboembolism in patients with colorectal cancer according to oncogenic status

    Clinical and Translational Oncology, Vol. 22, Núm. 11, pp. 2026-2031

  2. Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors

    Science Translational Medicine, Vol. 12, Núm. 565